ELTP - Elite Pharmaceuticals, Inc.
| Previous Close | 0.0670 |
| Open | 0.0660 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0620 - 0.0685 |
| 52 Week Range | 0.0300 - 0.1400 |
| Volume | 470,538 |
| Avg. Volume | 1,228,033 |
| Market Cap | 57.485M |
| Beta (5Y Monthly) | 1.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0070 |
| Earnings Date | Jun 18, 2020 - Jun 22, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- Thomson Reuters StreetEvents
Edited Transcript of ELTP earnings conference call or presentation 11-Feb-20 4:00pm GMT
Q3 2020 Elite Pharmaceuticals Inc Earnings Call
- ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2020 Ended December 31, 2019 and Provides Conference Call Information
Conference Call Scheduled for Tuesday, February 11th at 11:00 AM EST NORTHVALE, NJ / ACCESSWIRE / February 10, 2020 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), ...
- ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2020 Financial Results on February 11, 2020
Financials for Third Quarter Fiscal Year 2020 Ended December 31, 2020 will be released February 10, 2020 NORTHVALE, NJ / ACCESSWIRE / February 6, 2020 / Elite Pharmaceuticals, Inc. ("Elite" or ...
- ACCESSWIRE
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Elite Pharmaceuticals, Inc.- ELTP
NEW YORK, NY / ACCESSWIRE / January 9, 2020 / Levi & Korsinsky announces it has commenced an investigation of Elite Pharmaceuticals, Inc. (OTCQB:ELTP) concerning possible breaches of fiduciary duty. To ...
- ACCESSWIRE
Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals and SunGen Pharma Receive FDA Approval for Generic Adderall XR(R)
NORTHVALE, NJ / ACCESSWIRE / December 12, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing its own generic products, ...
- ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2020 Ended September 30, 2019 and Provides Conference Call Information
Conference Call Scheduled for Wednesday, November 13th at 11:00 AM EST NORTHVALE, NJ / ACCESSWIRE / November 12, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), ...
- ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2020 Financial Results on November 13, 2019
Financials for Second Quarter Fiscal Year 2020 Ended September 30, 2019 will be released November 12, 2019 NORTHVALE, NJ / ACCESSWIRE / November 6, 2019 / Elite Pharmaceuticals, Inc. ("Elite" ...
- ACCESSWIRE
Elite Pharmaceuticals Receives FDA Approval for Codeine and Acetaminophen Combo
NORTHVALE, NJ / ACCESSWIRE / September 12, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Tylenol® with Codeine (acetaminophen and codeine phosphate) 300mg/15mg, 300mg/30mg, and 300mg/60mg tablets. Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products. Elite specializes in oral sustained and controlled release drug products which have high barriers to entry.
- ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2020 Ended June 30, 2019 and Provides Conference Call Information
NORTHVALE, NJ / ACCESSWIRE / August 9, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the first quarter of fiscal year 2020 ended June 30, 2019 (“First Quarter”). Consolidated revenues for the First Quarter were $3.4 million, an increase of approximately 55% as compared to revenues for the comparable quarter of the prior fiscal year. The increase in revenues was largely attributed to revenues from the two products launched during the First Quarter, generic immediate release Adderall® and Dantrolene Capsules as well as continued growth in sales of Naltrexone tablets.
- ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2020 Financial Results on August 12, 2019
NORTHVALE, NJ / ACCESSWIRE / August 7, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that the first quarter financial results of the 2020 fiscal year will be released on Friday, August 9, 2019. Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products. Elite owns generic products which have been licensed to TAGI Pharma, Glenmark Pharmaceuticals, Inc., USA., and Lannett Company, Inc. Elite currently has twelve approved generic products, four generic products filed with the FDA, one approved generic products pending manufacturing site transfer, and an NDA filed for SequestOx™.
- ACCESSWIRE
Elite Pharmaceuticals Announces Commercial Launch of Dantrolene Capsules with Marketing Partner Lannett Company
NORTHVALE, NJ / ACCESSWIRE / June 28, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (ELTP) announced today that marketing partner Lannett Company, Inc. ("Lannett"), has commenced product launch of Elite's generic Dantrolene Capsules. Elite entered into a license, supply, and distribution agreement ("Agreement") with Lannett for Elite's Abbreviated New Drug Application (ANDA) for Dantrolene Sodium capsules, 25 mg, 50 mg and 100 mg. Elite's product is a generic version of Par Pharmaceutical's (an Endo International Company) Dantrium® (Dantrolene Sodium) which is indicated for controlling the manifestations of clinical spasticity. Lannett will be the exclusive U.S. distributor for Dantrolene Sodium capsules for which Elite will receive manufacturing fees and a profit split.
- ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2019 and Provides Conference Call Information
Conference Call Scheduled for Monday, June 24h at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / June 21, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB: ELTP), a specialty ...
- ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / June 17, 2019 / Elite Pharmaceuticals, Inc. (OTCQB: ELTP ) will be discussing their earnings results in their 2019 Fourth Quarter Earnings to be held on June 17, 2019 at 11:30 ...
- ACCESSWIRE
Elite Pharmaceuticals, Inc. Delays Fourth Quarter and Year End 2019 Earnings Release Date and Conference Call
Elite Pharmaceuticals, Inc. Delays Fourth Quarter and Year End 2019 Earnings Release Date and Conference Call NORTHVALE, NJ / ACCESSWIRE / June 14, 2019 / Elite Pharmaceuticals, Inc. ("Elite" ...
- ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Year-end Financial Results on June 17, 2019
Financials for Fiscal Year Ended March 31, 2019 will be released June 14, 2019 NORTHVALE, NJ / ACCESSWIRE / June 11, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB: ...
- GlobeNewswire
Elite Pharmaceuticals Enters into Strategic Marketing Alliance with Lannett For Generic Adderall®
The first product that Lannett will launch is a generic version of Adderall®, an immediate-release mixed salt of a single entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate) with strengths of 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, and 30 mg tablets. The second product is an extended-release CNS stimulant which is under review by the FDA. Under the Agreement, Lannett will provide sales, marketing, and distribution for the products and Elite will manufacture the product. Lannett, Elite and SunGen will each receive a share of the profits.
- GlobeNewswire
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2019 Ended December 31, 2018 and Provides Conference Call Information
Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the third quarter of fiscal year 2019 ended December 31, 2018 (“Third Quarter”). Consolidated revenues for the Third Quarter were $2.7 million, an increase of approximately 6% as compared to revenues for the comparable quarter of the prior fiscal year. Elite continues to invest in product development as $2.5 million was devoted to research and development expenses. During the Third Quarter, in addition to the launch of Methadone, Elite received FDA approval for generic Adderall®, and generic Norco®, and filed an ANDA for an antibiotic which was co-developed with SunGen.
- GlobeNewswire
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2019 Financial Results on February 12, 2019
Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that the third quarter financial results of the 2019 fiscal year will be released on Monday, February 11, 2019. Elite’s pipeline products include abuse-deterrent opioids which utilize the Company’s patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain.
- GlobeNewswire
Elite Pharmaceuticals and SunGen Pharma File ANDA for an Antibiotic
Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for a generic version of an antibiotic product. This is the third ANDA that Elite co-developed and filed with SunGen Pharma, LLC (“SunGen”). According to QVIA (formerly QuintilesIMS Health) data the branded product for this antibiotic and its equivalents had total annual U.S. sales of approximately $94 million for the twelve months ending September 30, 2018.
- GlobeNewswire
Elite Pharmaceuticals and SunGen Pharma Receive FDA Approval for Generic Adderall®
This is the first product approval for our Elite and SunGen Pharma LLC (“SunGen”) collaboration. The product is jointly owned. Elite will manufacture and package the product on a cost-plus basis and the parties are negotiating an agreement for sales of the product.
- GlobeNewswire
Elite Pharmaceuticals Receives FDA Approval for Hydrocodone and Acetaminophen Combo
Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it received approval from the U.S. Food and Drug Administration (FDA) for the Company’s abbreviated new drug application (ANDA) for a generic version of Norco (hydrocodone bitartrate and acetaminophen tablets, USP CII) 2.5mg/325mg, 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets. The combination products of hydrocodone and acetaminophen have total annual US sales of approximately $447 million according to IQVIA (formerly QuintilesIMS Health) data. “This is our fourth product approval in 2018 with four additional ANDAs and an NDA for SequestOx™ currently filed with the FDA,” stated Nasrat Hakim, President and CEO of Elite.
- GlobeNewswire
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2019 Ended September 30, 2018 and Provides Conference Call Information
Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the second quarter of fiscal year 2019 ended September 30, 2018 (“Second Quarter”). Consolidated revenues for the Second Quarter were $1.4 million, a decrease of approximately 16% as compared to revenues for the comparable quarter of the prior fiscal year. The decrease in revenues was largely attributed to lower revenues received from the manufacture of generic methadone, hydromorphone and phentermine. Elite continues to invest in product development as $2.5 million was devoted to research and development expenses. During the current fiscal year, Elite received FDA approval for generic Oxycodone/Acetaminophen and generic Methadone, achieved commercial launch of its methadone products and conducted several successful bio-equivalence studies.
- GlobeNewswire
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2019 Financial Results on November 12, 2018
Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that the second quarter financial results of the 2019 fiscal year will be released on Friday, November 9, 2018. Elite’s pipeline products include abuse-deterrent opioids which utilize the Company’s patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain.
- GlobeNewswire
Elite Pharmaceuticals Launches Generic Methadone Tablets
Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced the commercial launch of generic methadone hydrochloride 5mg and 10 mg tablets by Glenmark Pharmaceuticals, Inc., USA (“Glenmark”), Elite’s marketing alliance partner. Methadone can also be used for detoxification treatment of opioid addiction (heroin or other morphine-like drugs) or maintenance treatment of opioid addiction in conjunction with appropriate social and medical services. Through this alliance, Glenmark will sell and distribute certain of Elite’s generic products, including methadone, for which Elite will receive manufacturing and license fees.